A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

By sjmartinez • July 3, 2025

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Jul 1;199:96-102. doi: 10.1016/j.ygyno.2025.06.014. Epub ahead of print. PMID: 40602355.

Tags: Bevacizumab, Hematology/Oncology, maintenance therapy, Niraparib, ovarian cancer, Publications

Related Posts

The evolving role of ctDNA in colorectal cancer: guidance of adjuvant therapy or surveillance strategies?

Barrett LG, Gangi A, Hendifar A, Osipov A, Atkins K, Zaghiyan K, Nasseri Y, Murrell Z, Waters K, Mehta P, Zell JA, Hitchins MP, Gong[...]

Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight

Kim KJ, Zhong H, Tai D, Shah P, Park D, Goes V, Li J, Jung C, Kim L, Guzman S, Brar G, Castillo D. Microbiome[...]

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin[...]